Understanding how a protein from Pseudomonas aeruginosa interacts with enzymes related to cystic fibrosis.
Official title: Comparative structural and functional analysis of Pseudomonas aeruginosa inhibitor of vertebrate lysozyme paralogs
Funded at Kennesaw State University · NIH-10876400 · Data updated 2026-11-12
This study is looking at a protein from a bacteria that can cause infections in people with cystic fibrosis, to understand how it helps the bacteria survive and resist antibiotics, which could help find better ways to treat these infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kennesaw State University NIH-funded |
| Lab location | 1 site (Kennesaw, United States) |
| Project start | August 26, 2022 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $135,500 |
| NIH project number | 5R16AI167815-03 |
| Project ID | NIH-10876400 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with cystic fibrosis who are experiencing infections caused by Pseudomonas aeruginosa.
✕Less likely to help
Patients who do not have cystic fibrosis or are not infected with Pseudomonas aeruginosa may not benefit from this research.
What this research studies
This research investigates a protein called Inhibitor of Vertebrate Lysozyme protein 2 (IVYp2) from the bacteria Pseudomonas aeruginosa, which is known to cause infections in cystic fibrosis patients. The study aims to determine the structure of IVYp2 and how it interacts with specific enzymes that are crucial for bacterial survival and resistance to antibiotics. By using advanced techniques like NMR and enzyme inhibition assays, the researchers will explore how IVYp2 affects the activity of these enzymes in both laboratory settings and in genetically modified bacterial strains. This work could lead to a better understanding of how to combat antibiotic resistance in cystic fibrosis-related infections.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for treating infections in cystic fibrosis patients by overcoming antibiotic resistance.
How similar studies have gone: Other research has shown promise in targeting bacterial resistance mechanisms, but this specific approach is relatively novel.
Where this research is happening
-
Kennesaw State University
Kennesaw, United States Active
Researchers
- Principal investigator: Leeper, Thomas C — Kennesaw State University
- Study coordinator: Leeper, Thomas C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.